title: Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents.
abstract: A series of eight N(4)-phenylsubstituted-6-(2,4-dichlorophenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines 8-15 were synthesized as vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with varied substitutions in the phenyl ring of the 4-anilino moiety. In addition, five N(4)-phenylsubstituted-6-phenylmethylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines 16-20 were synthesized to evaluate the importance of the 2-NH(2) moiety for multiple receptor tyrosine kinase (RTK) inhibition. Cyclocondensation of alpha-halomethylbenzylketones with 2,6-diamino-4-hydroxypyrimidine afforded 2-amino-6-(2,4-dichlorophenylmethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one, 23 and reaction of alpha-bromomethylbenzylketones with ethylamidinoacetate followed by cyclocondensation with formamide afforded the 6-phenylmethylsubstituted-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-ones, 40-42, respectively. Chlorination of the 4-position and displacement with appropriate anilines afforded the target compounds 8-20. Compounds 8, 10 and 14 were potent VEGFR-2 inhibitors and were 100-fold, 40-fold and 8-fold more potent than the standard semaxanib, respectively. Previously synthesized multiple RTK inhibitor, 5 and the VEGFR-2 inhibitor 8 from this study, were chosen for further evaluation in a mouse orthotopic model of melanoma and showed significant inhibition of tumor growth, angiogenesis and metastasis.
authors.affiliation: Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, USA. gangjee@duq.edu
authors.forename: Aleem
authors.initials: A
authors.lastname: Gangjee
authors.forename: Sonali
authors.initials: S
authors.lastname: Kurup
authors.forename: Michael A
authors.initials: MA
authors.lastname: Ihnat
authors.forename: Jessica E
authors.initials: JE
authors.lastname: Thorpe
authors.forename: Satyendra S
authors.initials: SS
authors.lastname: Shenoy
mesh_terms: D020533:Angiogenesis Inhibitors / Q000138:chemical synthesis / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D003959:Diamines / Q000138:chemical synthesis* / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000517:prevention & control; D051379:Mice; D008819:Mice, Nude; D015394:Molecular Structure; D010766:Phosphorylation / Q000187:drug effects; D011743:Pyrimidines / Q000138:chemical synthesis* / Q000627:therapeutic use; D011744:Pyrimidinones / Q000737:chemistry / Q000494:pharmacology; D011758:Pyrroles / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D003959:Diamines; D007211:Indoles; D011743:Pyrimidines; D011744:Pyrimidinones; D011758:Pyrroles; C108140:4-hydroxypyrimidine; C116890:Semaxinib; D040301:Vascular Endothelial Growth Factor Receptor-2
references.citation: Bioorg Med Chem Lett. 2005 May 2;15(9):2225-30
references.pmid: 15837298
references.citation: J Med Chem. 2006 Feb 9;49(3):1055-65
references.pmid: 16451071
references.citation: Acc Chem Res. 2003 Jun;36(6):462-9
references.pmid: 12809533
references.citation: Curr Opin Struct Biol. 2002 Dec;12(6):735-41
references.pmid: 12504677
references.citation: Oncologist. 2004;9 Suppl 1:2-10
references.pmid: 15178810
references.citation: J Med Chem. 1998 Apr 23;41(9):1409-16
references.pmid: 9554874
references.citation: Nat Rev Cancer. 2007 May;7(5):332-44
references.pmid: 17457301
references.citation: Eur J Cancer. 2006 Jul;42(10):1351-6
references.pmid: 16740386
references.citation: Nat Rev Drug Discov. 2006 Apr;5(4):279-80
references.pmid: 16628834
references.citation: J Med Chem. 1999 Dec 30;42(26):5369-89
references.pmid: 10639280
references.citation: J Med Chem. 1996 Nov 8;39(23):4563-8
references.pmid: 8917644
references.citation: Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4446s-4450s
references.pmid: 16857826
references.citation: J Investig Dermatol Symp Proc. 2000 Dec;5(1):24-33
references.pmid: 11147671
references.citation: Nat Rev Drug Discov. 2006 Oct;5(10):835-44
references.pmid: 17016424
references.citation: J Pharmacol Exp Ther. 2005 Dec;315(3):971-9
references.pmid: 16002463
references.citation: Cancer Res. 1994 Dec 1;54(23):6106-14
references.pmid: 7954456
references.citation: Cancer Res. 2000 Aug 1;60(15):4152-60
references.pmid: 10945623
references.citation: Chem Biol. 2005 Jun;12(6):621-37
references.pmid: 15975507
references.citation: Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4421s-4425s
references.pmid: 16857821
references.citation: Br J Cancer. 2006 Mar 13;94(5):614-9
references.pmid: 16465192
references.citation: Trends Mol Med. 2002;8(4 Suppl):S14-8
references.pmid: 11927282
references.citation: J Med Chem. 1995 Sep 1;38(18):3482-7
references.pmid: 7658435
references.citation: Bioorg Med Chem. 2003 Nov 17;11(23):5155-70
references.pmid: 14604679
references.citation: Nat Rev Cancer. 2002 Oct;2(10):727-39
references.pmid: 12360276
references.citation: Drug Discov Today. 2000 Aug;5(8):344-353
references.pmid: 10893547
references.citation: J Med Chem. 2000 Jun 15;43(12):2310-23
references.pmid: 10882357
references.citation: Cell Prolif. 1999 Apr-Jun;32(2-3):131-40
references.pmid: 10535359
references.citation: Nat Med. 2003 Jun;9(6):669-76
references.pmid: 12778165
references.citation: J Med Chem. 2002 Dec 19;45(26):5687-93
references.pmid: 12477352
references.citation: Nat Rev Drug Discov. 2007 Apr;6(4):273-86
references.pmid: 17396134
references.citation: J Med Chem. 2002 Mar 14;45(6):1300-12
references.pmid: 11881999
references.citation: PLoS Med. 2005 Mar;2(3):e73
references.pmid: 15737014
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: Clin Cancer Res. 2001 Oct;7(10):2958-70
references.pmid: 11595683
references.citation: Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117
references.pmid: 12678905
references.citation: Chem Pharm Bull (Tokyo). 1995 May;43(5):788-96
references.pmid: 7553966
references.citation: J Med Chem. 2008 Aug 28;51(16):4890-8
references.pmid: 18680272
references.citation: Bioorg Med Chem Lett. 2005 May 2;15(9):2203-7
references.pmid: 15837294
references.citation: Clin Biochem. 2004 Jul;37(7):618-35
references.pmid: 15234243
references.citation: J Med Chem. 1996 Jan 5;39(1):267-76
references.pmid: 8568816
references.citation: J Med Chem. 2005 Mar 10;48(5):1610-9
references.pmid: 15743202